Ranbaxy Laboratories Signs Drug Discovery Development Pact With Merck & Co., Inc.
Life Sciences is the next big thing to IT and that is happening to India now, Ranbaxy to develop anti-infective drugs for Merck...
India's Ranbaxy Laboratories Ltd. (Ranbaxy) is to develop new anti-infective drugs for Merck & Co Inc, (Merck) in a major deal underlining the growing use of Indian pharmaceutical research by multinational Companies.
Ranbaxy and Merck announced today that they have signed a strategic Product Development Agreement (the “Agreement”) providing for a drug discovery and clinical development collaboration for new products, in the anti-infective field. Potential Payments Totaling More than $100 Million .
Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry-out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates thereafter.
The Indian group will get an undisclosed upfront sum and could receive more than $100 million for each drug target, depending on successful development and regulatory approval. It will also be entitled to royalties under the five-year deal.
India's Ranbaxy Laboratories Ltd. (Ranbaxy) is to develop new anti-infective drugs for Merck & Co Inc, (Merck) in a major deal underlining the growing use of Indian pharmaceutical research by multinational Companies.
Ranbaxy and Merck announced today that they have signed a strategic Product Development Agreement (the “Agreement”) providing for a drug discovery and clinical development collaboration for new products, in the anti-infective field. Potential Payments Totaling More than $100 Million .
Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry-out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates thereafter.
The Indian group will get an undisclosed upfront sum and could receive more than $100 million for each drug target, depending on successful development and regulatory approval. It will also be entitled to royalties under the five-year deal.
Comments